Novocure (NVCR) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Novocure Reports First Quarter 2016 Financial Results and Provides Company Update
May 9, 2016 4:00 PM EDTIncreasing adoption of Optune with 755 prescriptions received in the first quarter 2016, an increase of 73 percent from the first quarter 2015 and 36 percent from the fourth quarter 2015
797 active patients at March 31, 2016, an increase of 114 percent from March 31, 2015 and 32 percent from December 31, 2015
First quarter 2016 reported revenues of $13.1 million, reflecting 151 percent growth versus first quarter 2015
More than 112 million Americans have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma
Phase 2 pilot PANOVA results presented at ASCO GI suggest Tumor Treating Fields plus chemotherapy may be safe as first-line treatment and improve survival of patients... More
